top of page

"Founded by Italian research scientist Jonathan Fior, Innovative Bioresearch Ltd. is a biotech company bringing disruptive innovation to pharma using blockchain technology to decentralize biomedical research"

CORE TEAM

Jonathan Fior, the CEO of Innovative Bioresearch
Jonathan Fior
Owner and Chief Scientific Officer

Jonathan Fior was born in Los Angeles, USA, in 1982, to Italian parents. Jonathan’s parents moved back to Italy when he was a child, and he completed his education in Italy, a country known for its excellence in the education department. He was always fascinated by science and graduated with a bachelor's degree in medical biotechnology from the University of Milan, Italy. He immediately started working in the field of HIV research, with the goal of bringing innovation to the field. In this regard, he conceived the idea of using irradiated SupT1 cells as a decoy target for HIV-1 to prevent CD4+ T cell depletion as well as to render the virus less cytotoxic. Jonathan explored this approach in an in vitro setting in his 2012 publication, proposing SupT1 cell infusion as a possible cell-based HIV therapy. He then wanted to explore this novel therapeutic approach in an in vivo setting. He decided to start his own research company and founded Innovative Bioresearch in 2014. He later conducted a groundbreaking pilot study exploring SupT1 cell infusion therapy for HIV in humanized mice and was the first research scientist to believe in the potential of blockchain technology to disrupt pharma, issuing INNBC (InnovativeBioresearchCoin) in 2018. He is also the author of what can be considered the most comprehensive scientific paper on the Salamander regeneration process, how it compares with human healing, and how it can be a model for developing novel regenerative and anticancer therapies. Recently, he published the first peer-reviewed decentralized science (DeSci) study, demonstrating the real world use of INNBC DApp for blockchain-based biomedical data storage and sharing, on Springer-Nature network, leading publisher of the world's most prestigious scientific journals.  

Enrico Durante, the marketing diretor of Innovative Bioresearch
Enrico Durante
Marketing Director and
Executive Consultant

Enrico Durante is an experienced marketer specialized in Management, Growth Hacking, Business Development, Marketing, and blockchain knowledge. One of his strongest qualities is that he always puts himself in the client's shoes. Every project has its own target audience with their own needs, expectations, tastes, etc. When starting a project, he always takes his time to carefully plan, research, and experiment before kicking off with the final strategies. He also operates locally to provide direct assistance to Italian commercial activities using INNBC as a means of payment; you can see him in action in this video filmed at one of the largest construction companies in Messina, Italy, accepting INNBC as a means of payment.

Michael Odi, the community manager of Innovative Bioresearch
Michael Odi 
Community Manager 
Alessandro Gatti, the legal expert of Innovative Bioresearch
Alessandro Gatti
Chief Legal Officer

Michael is our strong and hard working community manager, doing his best to also moderate our very active Telegram group (https://t.me/innovativebioresearch), which can get very wild sometimes! 

Alessandro Gatti is a legal expert and he ensures that everything we do is in accordance with the law.

HOW WE OPERATE

For biomedical research projects, Jonathan Fior works as PI (principal investigator), conceiving the experiments and writing the experiment protocol. The work is then assigned to a Contract Research Organization (CRO), which physically performs the experiments. Jonathan Fior then supervises all aspects related to the research, communicating closely with the CRO. Once the experiments are completed, he analyzes the results and writes a scientific paper, which is published in a peer-reviewed scientific journal. This means that although our team is not large, we actually have companies with 100+ people working for us. For example, for our HIV study in humanized mice, we used a state-of-the-art CRO company such as AXENIS, a spin-off of the Institut Pasteur (Paris, France), which has now been acquired by Genoway. This way, we can keep a small, yet strong and great, team. We only publish in open-access scientific journals because we believe in free information and don’t want our data to be hidden behind a paywall. For software projects, they are developed internally. 

bottom of page